This session from APCCC 2026 features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in current practices, challenges, and future directions in radiopharmaceuticals.
Episode 498: APCCC 2026 - mCRPC
02/05/2026 | 21 min
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-driven therapy, and emerging treatment options.
Episode 497: Reflections on the capivasertib ODAC
01/05/2026 | 21 min
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.
Episode 496: APCCC 2026 - mHSPC Landscape
01/05/2026 | 26 min
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer
30/04/2026 | 31 min
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment decisions.
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Colombia